2 Companies Stumble Over PAH; Therapies Prove Difficult
By Peter Winter
Monday, August 27, 2012
Finding next-generation treatments for pulmonary arterial hypertension (PAH) is proving to be difficult. Last week two companies made the point. Gilead Sciences Inc. terminated a Phase II trial of cicletanine for PAH due to a failure of the trial to meet its primary endpoint of improvement in exercise capacity; and Novartis AG pulled its new drug application (NDA) for QTI571 (imatinib mesylate) for PAH treatment.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.